drugset / Trial / NCT00360425

A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women

NCT00360425 ↗

Phase 1 Completed 174 enrolled AMAG Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will define the effects of ferumoxytol on electrocardiogram (ECG) data as well as evaluate pharmacokinetics

Timeline

Start
2006-05
Primary completion
—
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxytol Diagnostic / imaging agent — —
Subject Moxifloxacin Small molecule — —

Indications